Literature DB >> 12081208

Frequent phosphorylation at serine 392 in overexpressed p53 protein due to missense mutation in carcinoma of the urinary tract.

Mutsuo Furihata1, Atsushi Kurabayashl, Manabu Matsumoto, Hiroshi Sonobe, Yuji Ohtsuki, Naotami Terao, Morimasa Kuwahara, Taro Shuin.   

Abstract

Post-transcriptional modification of p53 by phosphorylation has been proposed to be an important mechanism of p53 stabilization and functional regulation. Phosphorylation of p53 Ser392, in particular, activates specific DNA binding functions by stabilizing p53 tetramer formation. This study evaluated the relationship between p53 Ser392 phosphorylation and various types of p53 missense mutation detected in urothelial transitional cell carcinomas (TCCs), with stratification of the mutations according to the functional domains elucidated by the crystal structure of the p53 protein. Of 41 TCCs with missense mutations, 26 (63.4%) exhibited immunopositivity with Ser392 phospho-specific p53 antibody. In comparison to structural mutations, the missense mutations at exon 7 (p=0.0307) or located in regions that affect direct DNA binding ability (p = 0.0273) were significantly associated with Ser392 immunopositivity. No statistically significant relationship was found between Ser392 immunoreactivity and other different types of p53 mutation. The prevalence of cases exhibiting Ser392-positive immunostaining was higher for high-grade (p <0.0001) and advanced-stage TCCs (p =0.0119) than for TCCs with wild-type p53. No significant relationship was found between Ser392 immunoreactivity and apoptotic index in urothelial TCCs. These in vivo findings indicate that Ser392 phosphorylation frequently occurs in mutant form p53 in TCCs. Because mutant form p53 can act dominant-negatively by heterooligomerization with wild-type p53, these findings also suggest that Ser392 phosphorylation might activate tetramer formation to promote the dominant-negative effects of mutant form p53, and thereby contribute to proliferation of aggressive TCCs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12081208     DOI: 10.1002/path.1082

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  9 in total

Review 1.  Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology.

Authors:  James W Mandell
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

Review 2.  Posttranslational phosphorylation of mutant p53 protein in tumor development.

Authors:  Manabu Matsumoto; Mutsuo Furihata; Yuji Ohtsuki
Journal:  Med Mol Morphol       Date:  2006-06       Impact factor: 2.309

3.  Age-dependent copy number variations of TP53 tumour suppressor gene associated with altered phosphorylation status of p53 protein in sporadic schwannomas.

Authors:  Hongsai Chen; He Huang; Jingjing Zhao; Zhigang Wang; Mengling Chang; Lu Xue; Weidong Zhu; Yongchuan Chai; Gen Li; Zhaoyan Wang; Hao Wu
Journal:  J Neurooncol       Date:  2019-05-02       Impact factor: 4.130

Review 4.  Mutant TP53 posttranslational modifications: challenges and opportunities.

Authors:  Thuy-Ai Nguyen; Daniel Menendez; Michael A Resnick; Carl W Anderson
Journal:  Hum Mutat       Date:  2014-02-11       Impact factor: 4.878

5.  Association of TP53 gene polymorphisms with susceptibility of bladder cancer in Bangladeshi population.

Authors:  Md Bayejid Hosen; Md Abdus Salam; Md Fakhrul Islam; Ashfaque Hossain; M Zakir Hossain Hawlader; Yearul Kabir
Journal:  Tumour Biol       Date:  2015-03-25

Review 6.  Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.

Authors:  Xuetian Yue; Yuhan Zhao; Yang Xu; Min Zheng; Zhaohui Feng; Wenwei Hu
Journal:  J Mol Biol       Date:  2017-04-06       Impact factor: 5.469

7.  Relationship between VEGF and p53 expression and tumor cell proliferation in human gastrointestinal carcinomas.

Authors:  Elvira Montero; Carmen Abreu; Paola Tonino
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-17       Impact factor: 4.553

8.  p53 codon 72 polymorphism as a progression index for bladder cancer.

Authors:  Hung-Yu Lin; Chun-Hsiung Huang; Tsan-Jung Yu; Wen-Jen Wu; Ming-Chang Yang; For-Wey Lung
Journal:  Oncol Rep       Date:  2011-12-22       Impact factor: 3.906

9.  Metformin inhibits the development, and promotes the resensitization, of treatment-resistant breast cancer.

Authors:  Gerald Davies; Liubov Lobanova; Wojciech Dawicki; Gary Groot; John R Gordon; Matthew Bowen; Troy Harkness; Terra Arnason
Journal:  PLoS One       Date:  2017-12-06       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.